16.07.2007 20:49:00
|
Richard Croarkin Appointed CFO of Alcon
Alcon, Inc. (NYSE:ACL) announced today that effective August 1, Richard
Croarkin will be named senior vice president and chief financial
officer. Croarkin comes to Alcon from Nestlé,
SA, where he was executive vice president finance and chief financial
officer of Nestlé Waters North America.
"I am excited to welcome Rick to Alcon and
expect that with his extensive background in global finance he will
provide excellent leadership to the experienced financial team we have
at Alcon,” said Cary Rayment, Alcon’s
chairman, president and chief executive officer, "During
his 30 year career Rick has worked around the world in senior financial
positions which has prepared him to step into his new role.” "Alcon has had an enviable record of
performance since its IPO and I am looking forward to the opportunity to
help the company continue this success into the future,”
Croarkin said.
Croarkin joined Nestlé Waters North America
in 1994 and he has overseen the finances of a business unit that has
grown to $4.4 billion in sales. He has responsibility for all aspects of
finance including financial planning, treasury, tax, accounting,
controls, credit, information systems and acquisitions. Before joining
Nestlé, Croarkin worked for Pepsico
Incorporated for 11 years, where he served in a number of senior
financial positions around the world, including as chief financial
officer of Pepsi Latin America and Pepsi Canada. He started his career
with AMAX, Inc. and worked in treasury, corporate development and
planning. Croarkin is a 1976 graduate of Georgetown University with a
degree in economics and received his MBA from University of Connecticut
in 1979. He also has a diploma of the French language from Alliance
Francaise in Paris, France. During his career he has gained extensive
global experience by serving in a variety of key financial positions in
several countries.
About Alcon
Alcon, Inc. is the world’s leading eye care
company, with sales of approximately $4.9 billion in 2006. Alcon, which
has been dedicated to the ophthalmic industry for 60 years, researches,
develops, manufactures and markets pharmaceuticals, surgical equipment
and devices, contact lens care solutions and other vision care products
that treat diseases, disorders and other conditions of the eye. Alcon’s
majority shareholder is Nestlé, S.A., the
world’s largest food company.
Caution Concerning Forward-Looking Statements. This press
release may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any forward-
looking statements reflect the views of our management as of the date of
this press release with respect to future events and are based on
assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. Except to the extent required under the
federal securities laws and the rules and regulations promulgated by the
Securities and Exchange Commission, we undertake no obligation to
publicly update or revise any of these forward-looking statements,
whether to reflect new information or future events or circumstances or
otherwise.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Novartis AGmehr Nachrichten
02.12.24 |
Aufschläge in Zürich: SMI schlussendlich fester (finanzen.at) | |
02.12.24 |
Starker Wochentag in Europa: STOXX 50 nachmittags in Grün (finanzen.at) | |
02.12.24 |
SIX-Handel: SMI mit positivem Vorzeichen (finanzen.at) | |
02.12.24 |
SMI-Titel Novartis-Aktie: So viel Gewinn hätte ein Investment in Novartis von vor 3 Jahren eingefahren (finanzen.at) | |
29.11.24 |
Zuversicht in Zürich: SLI verbucht zum Handelsende Gewinne (finanzen.at) | |
29.11.24 |
Optimismus in Zürich: SMI legt letztendlich zu (finanzen.at) | |
29.11.24 |
Zurückhaltung in Zürich: SMI liegt am Freitagnachmittag im Minus (finanzen.at) | |
29.11.24 |
Optimismus in Europa: So entwickelt sich der STOXX 50 aktuell (finanzen.at) |
Analysen zu Novartis AGmehr Analysen
25.11.24 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
22.11.24 | Novartis Hold | Deutsche Bank AG | |
22.11.24 | Novartis Neutral | Goldman Sachs Group Inc. | |
21.11.24 | Novartis Neutral | Goldman Sachs Group Inc. | |
21.11.24 | Novartis Underweight | Barclays Capital |
Aktien in diesem Artikel
Novartis AG | 80,10 | -0,27% |
Indizes in diesem Artikel
NYSE US 100 | 17 412,16 | 0,21% |